Clarifying the link between cannabis use and risk for psychosis

Acta Psychiatrica Scandinavica

Volumn 136, Issue 1, 2017, Pages 3-4

  Weiss, S R B ^a   Blanco, C ^a   Wargo, E M ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AKT1 PROTEIN; CANNABIS; CATECHOL METHYLTRANSFERASE; DRD2 PROTEIN; PROTEIN; UNCLASSIFIED DRUG; CANNABINOID;

ALCOHOL CONSUMPTION; CANNABIS USE; DNA METHYLATION; DRUG DEPENDENCE; EDITORIAL; GENETIC RISK; HIGH RISK POPULATION; HUMAN; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROMOTER REGION; PSYCHOSIS; RISK FACTOR; SCHIZOPHRENIA; SCHIZOTYPAL PERSONALITY DISORDER; TOBACCO USE; CANNABIS ADDICTION;

CANNABINOIDS; CANNABIS; HUMANS; MARIJUANA ABUSE; PSYCHOTIC DISORDERS; RISK FACTORS;

EID: 85019702207     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/acps.12764     Document Type: Editorial

References (12)

1. Blanco C, Hasin DS, Wall MM et al. Cannabis use and risk of psychiatric disorders: prospective evidence from a US national longitudinal study. JAMA Psychiatry 2016;73:388–395.
2. Carney R, Cotter J, Firth J, Bradshaw T, Yung AR. Cannabis use and symptom severity in individuals at ultra high risk for psychosis: a meta-analysis. Acta Psychiatr Scand 2017;136:5–15.
3. Carney R, Cotter J, Bradshaw T, Firth J, Yung AR. Cardiometabolic risk factors in young people at ultra-high risk for psychosis: a systematic review and meta-analysis. Schizophr Res 2016;170:290–300.
4. Fernandez-Espejo E, Viveros MP, Núñez L et al. Role of cannabis and Endocannabinoids in the genesis of schizophrenia. Psychopharmacology 2009;206:531–549.
5. D'Addario C, Micale V, Di Bartolomeo M et al. A preliminary study of endocannabinoid system regulation in psychosis: distinct alterations of CNR1 promoter DNA methylation in patients with schizophrenia. Schizophr Res 2017. https://doi.org/10.1016/j.schres.2017.01.022.
6. Keyes KM, Eaton NR, Krueger RF et al. Childhood maltreatment and the structure of common psychiatric disorders. Br J Psychiatry 2012;200:107–115.
7. Blanco C, Rafful C, Wall MM, Ridenour TA, Wang S, Kendler KS. Towards a comprehensive developmental model of cannabis use disorders. Addiction 2014;109:284–294.
8. Davis GP, Compton MT, Wang S, Levin FR, Blanco C. Association between cannabis use, psychosis, and schizotypal personality disorder: findings from the National Epidemiologic Survey on Alcohol and Related Conditions. Schizophr Res 2013;151:197–202.
9. Keyes KM, Eaton NR, Krueger RF et al. Thought disorder in the meta-structure of psychopathology. Psychol Med 2013;43:1673–1683.
10. Colizzi M, Iyegbe C, Powell J et al. Interaction between functional genetic variation of DRD2 and cannabis use on risk of psychosis. Schizophr Bull 2015;41:1171–1182.
11. Di Forti M, Iyegbe C, Sallis H et al. Confirmation that the AKT1 (rs2494732) genotype influences the risk of psychosis in cannabis users. Biol Psychiatry 2012;72:811–816.
12. Caspi A, Moffitt TE, Cannon M et al. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biol Psychiatry 2005;57:1117–1127.